Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force.
about
Management of bleeding and coagulopathy following major trauma: an updated European guideline.Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaThe European guideline on management of major bleeding and coagulopathy following trauma: fourth editionFailure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding.Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.Diminished response to recombinant factor VIIa in a patient with idiopathic thrombocytopenic purpura.Recombinant Activated Factor VII (rFVIIa) in the Management of Major Obstetric Haemorrhage: A Case Series and a Proposed Guideline for Use.Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indicationsManagement of bleeding following major trauma: an updated European guideline.Recombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patientsRecombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trialsEvaluation of recombinant factor VIIa treatment for massive hemorrhage in patients with multiple traumasPreanesthetic Assessment of the Jehovah's Witness Patient.Recombinant Factor VIIa in Post-partum Hemorrhage: A New Weapon in Obstetrician's Armamentarium.Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.Recombinant activated factor VIIa and hemostasis in critical care: a focus on traumaManagement of bleeding following major trauma: a European guideline.The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage.Management of bleeding emergencies: when to use recombinant activated factor VII.Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trialA critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions.Recombinant-activated coagulation factor VIIa (NovoSeven): current development.Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven)Blood management: a primer for clinicians.Overview of the human pharmacokinetics of recombinant activated factor VII.Recombinant activated factor VII (Novo7) in patients with ventricular assist devices: case report and review of the current literatureOff-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials.The role of recombinant activated Factor VII in major obstetric haemorrhage: the Farnborough experience.Recombinant activated factor VII in post partum haemorrhage.Hemostatic and neuroprotective effects of human recombinant activated factor VII therapy after traumatic brain injury in pigs.Recombinant activated factor VII as a promising adjuvant therapy for postpartum hemorrhage in the practice of obstetric anesthesia: experience from a university hospital in Taiwan.Emerging treatment strategies for trauma-induced coagulopathy.Timely 'off-label' use of recombinant activated factor VII (NovoSeven(®)) can help in avoiding hysterectomy in intractable obstetric bleeding complicated with disseminated intravascular coagulation: A case report and review of the literature.The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding.Practical management of major blood loss.Predictive Models and Algorithms for the Need of Transfusion Including Massive Transfusion in Severely Injured PatientsSuccessful use of recombinant activated factor VII for postoperative associated haemorrhage: a case reportUncontrolled haemorrhage in pelvic fracturesd---Can the inevitable be avoided?Acute traumatic coagulopathy: Incidence, risk stratification and therapeutic options.
P2860
Q21092902-123E60A1-6AA8-495E-999A-1B9C1B1A844AQ24236583-8F84AA86-3B92-45E3-A6B4-1352C762261FQ24245204-70B42DB1-E117-4448-91B2-C59706B0B5A9Q27339343-354AA285-80A4-4E90-96FF-B9BBE27B3DACQ33282917-AE4046BB-0297-4E15-922F-0E44EF068270Q33369021-5827E32A-FDAF-475A-8638-45675DC597D8Q33373076-C2E6078A-2A5D-489D-933A-F197CF33B07CQ33633854-EB8D9C37-5CA4-424E-B6CA-433EABF80E80Q33876266-3F448C82-2678-4E82-8AF3-8E4E4AA9D7A3Q33919178-B1008572-AC5E-439A-9F8D-1788DB01233AQ34604004-244502AC-FBE5-4CC7-8200-0AC476F1F1F4Q35629970-98296C08-89EC-4B04-9623-688BF5EA0823Q35788608-720C0D66-6771-472A-A913-813EFCC593E0Q35839379-D866518C-4CBA-4F75-B6E3-F3482A0A22B6Q35906504-640FD2E9-4424-4875-AE25-35C6B476EAE6Q36284640-66A525E3-5489-4494-9D1F-2B2CA82EBCA2Q36284647-2F3534E9-24DB-4A8C-AAD2-9DC8D1CAEAC0Q36296517-11E48C29-9DF4-4ECE-9672-AC6AD64286E5Q36349573-389CEBF7-B189-4BD9-BC51-56FF1EB4AD7EQ36349585-3085A956-6011-4D18-A6E7-EE180641F912Q36392691-C3038B43-3E79-4B20-A772-EB7F1679883CQ36462093-9443B3C6-8EEF-487B-8C2E-993DE53E7F71Q36800526-908C4719-F18E-45BC-ADE2-E4BF974EE0A3Q36839258-D9C133FD-6DB6-4EE2-A817-5FF66B0F416DQ36951995-1D2403D3-B821-4D9D-A43D-092672440A36Q36981748-FA670682-099F-4CFC-953B-29BD9D0A2101Q36982713-EB56D865-3B6B-4434-B6EB-3CEE1A0BEA43Q37147203-08DCD0FB-3C89-4542-AD64-AE24E633747DQ37413124-8E85998C-CB50-4735-BC31-BE670E2222BCQ37443253-939E0362-B9F9-4C92-A31E-A5D75BA1D99AQ37691716-009E19D3-AD47-4B5F-AD22-B3624C6CE7A1Q37898741-9937741C-AF0D-4A5A-97B1-C51C644D5BCBQ37996341-2F528455-6DA0-4D8C-A814-23A944A9AB90Q38005104-0EF5B7CD-924E-475A-8F50-B3CA60EF4312Q38072765-6D9FA831-3E74-4BC0-8A88-2929B648A852Q38273787-09CA922A-FC98-4688-AA20-3ADE106D0C35Q41818425-B89BA907-A58A-4F39-ACAF-1781EAEFAA1CQ41820542-4122D8D7-506F-4114-AAEA-840D09E71DDFQ41856593-C89B1F9C-851B-43D7-8CB7-96E687C01795Q41868264-8D686A27-BA64-4D6A-9B53-A8B4FE2ECBD2
P2860
Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Guidelines for the use of reco ...... isciplinary rFVIIa Task Force.
@en
Guidelines for the use of recombinant activated factor VII
@nl
type
label
Guidelines for the use of reco ...... isciplinary rFVIIa Task Force.
@en
Guidelines for the use of recombinant activated factor VII
@nl
prefLabel
Guidelines for the use of reco ...... isciplinary rFVIIa Task Force.
@en
Guidelines for the use of recombinant activated factor VII
@nl
P2093
P1476
Guidelines for the use of reco ...... isciplinary rFVIIa Task Force.
@en
P2093
Israeli Multidisciplinary rFVIIa Task Force
M Michaelson
U Martinowitz
P2860
P304
P356
10.1111/J.1538-7836.2005.01203.X
P577
2005-04-01T00:00:00Z